Answers are grounded in this paper and cite their sources.
0.052), respectively, compared with untreated muscle (28.0 ± 4.4 mg) and the formation of grossly normal vascularized skeletal muscle in the defect region. Additionally, decellularized grafts were equivalent to cell-seeded TEMGs in force regeneration while producing a significantly lower macrophage response at 28 days. In summary, it was demonstrated that myoblast-secreted ECM scaffolds provide a similar regenerative outcome to cellularized TEMGs while mitigating the inflammatory response.Impact StatementVolumetric muscle loss (VML) results in significant chronic morbidity. Clinical treatment with muscle flaps results in limited regeneration. Tissue-engineered muscle grafts have been used to restore muscle mass and function in preclinical models but are not immediately translatable. Decellularized tissue-derived materials have been approved but thus far show limited generation of muscle tissue in large injuries. We propose a novel regenerative extracellular matrix (ECM) scaffold with a controlled structure derived from skeletal muscle myoblasts. We demonstrate that a 50% VML model undergoes significant regeneration when treated with myoblast ECM scaffolds.
No takes yet. Share an insight, caveat, or question.
Dias et al. (2026) studied this question.
Synapse has enriched 8 closely related papers on similar clinical questions. Consider them for comparative context: